Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM919 in advanced solid tumors
NCT06328673Phase 1Active, not recruiting
- Sponsor
- D2M Biotherapeutics
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of DM919 in solid tumor (advanced stage) (4 arms), sponsored by D2M Biotherapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Recommended Dose for Expansion or Recommended Phase 2 Dose at 24 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
DM919
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06328673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328673.